spacer
home > ebr > spring 2002 > has biotechnology forgotten the eye?
PUBLICATIONS
European Biopharmaceutical Review

Has Biotechnology Forgotten the Eye?

For over two decades, the biotechnology industry has been developing therapeutic products based on large molecules. The majority of these products are proteins, from the first trailblazers such as insulin and growth hormone, to the blockbusters like EPO, and subsequently wider classes of molecules such as cytokines, enzymes and antibodies. Yet in all this time, there have been few chronic clinical studies of proteins in eye disease. This is not because the markets are unattractive. Millions of patients suffer from poorly treated diseases in ophthalmology - such as age-related macular degeneration (AMD), or diabetic retinopathy - yet there are still very few medical treatments available. The exception that clearly demonstrates the attractive nature of the ophthalmology market is Visudyne’, developed by QLT Therapeutics Inc. and Novartis. The product transformed QLT from a small Canadian cancer company into a significantly capitalised, internationally known biotech company. This change occurred when the QLT concept of photodynamic therapy, which had previously been applied for several years to cancer with limited success, was applied to AMD. So given this success, why is biotech activity so limited in the eye?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Tom S Shepherd, President and Chief Executive Officer of Neurotech S.A.

Dr Tom Shepherd is President and Chief Executive Officer of Neurotech S.A., a French-based biotechnology company based in the Genopole science park in Evry near Paris, with a US R&D subsidiary based in Lincoln, Rhode Island. Prior to joining the company in 1998, he was Vice President of Business Development at Intrabiotics Inc, a Californian biotech company now quoted on Nasdaq.
Tom gained his PhD in Biochemistry from the University of Strathclyde in Glasgow, UK, and has 20 years of international management experience in pharmaceuticals and biotechnology, having worked in the UK, the US, Australia, South Korea and France, with a range of companies including Sandoz (now Novartis), Cortecs plc, and ICN Pharmaceuticals.

spacer
Dr Tom S Shepherd
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement